Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection

Launched by BEIJING TIANTAN HOSPITAL · Feb 6, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called tranexamic acid can help reduce blood loss during surgery for large meningiomas, which are tumors found in the brain. Previous research has shown that using tranexamic acid in other types of surgeries can lower blood loss, but there hasn’t been much focus on its effects in brain surgeries. Since patients undergoing surgery for large meningiomas often lose a significant amount of blood, this study aims to see if tranexamic acid can make a difference.

To be eligible for this trial, participants must be between 18 and 65 years old and scheduled for surgery to remove a meningioma that is larger than 5 centimeters. They also need to be in good health according to certain medical guidelines and must provide written consent to participate. If someone is allergic to tranexamic acid or has a history of certain medical conditions, they won't be able to join the study. Those who participate will receive either the medication or a placebo during their surgery, and the team will monitor their blood loss and recovery. This research could potentially lead to better outcomes for patients with large meningiomas in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing elective supratentorial meningioma resection with estimated tumor diameter \>5cm on brain image.
• • Age between 18-65 years.
• • American Society of Anaesthesiologist (ASA) physical status Ⅰ to Ⅲ
• • Obtain written informed consent.
• Exclusion Criteria:
• • Allergic to tranexamic acid.
• • History of thrombotic disease.
• • History of chronic kidney disease
• • Receiving other anticoagulation or antiplatelet treatment.
• • Refuse to provide written informed consent